Provectus Biopharmaceuticals Inc.’ Data On PV-10 As Treatment For Melanoma Presented At 5th European Post-Chicago Melanoma / Skin Cancer Meeting

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT,, a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), today announced that Dr. Vernon Sondak (Moffitt Cancer Center, Tampa, FL, USA) presented data on “Intralesional Therapy for Melanoma with PV-10” during the 5th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany.

Help employers find you! Check out all the jobs and post your resume.

Back to news